Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic ...

October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Schaal discussed bacterial diseases in layers. According to Schaal, there are three elements impacting poultry immune health and performance — the bird, the environment and the pathogens — also known ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for ...